Polen Capital, an investment management company, released its “Polen U.S. Small Company Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q1 2025, optimism fueled by the Trump election shifted to fear and uncertainty due to apprehension about cost-cutting measures and emerging trade policies. In the first quarter, the fund delivered -10.53% gross, and -10.83% net of fees, compared to a -11.12% return for the Russell 2000 Growth Index. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025.
In its first-quarter 2025 investor letter, Polen U.S. Small Company Growth Strategy highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.722 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -1.41%, and its shares lost 40.99% of their value over the last 52 weeks. On May 13, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $51.61 per share.
Polen U.S. Small Company Growth Strategy stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:
“During the quarter, we initiated a new position in Bio-Techne Corporation (NASDAQ:TECH) and added to several existing positions.
Bio-Techne is a premier provider of life sciences tools and reagents, serving highly specialized niches and delivering mission-critical solutions for its customers. The company provides tools for advanced research in areas like proteomics, cell and gene therapy, and precision medicine. Although recent concerns about biotech end markets and funding may weigh on sentiment in the short term, we remain confident in the company’s ability for long-term growth through innovation, disciplined M&A, and solid execution. We believe Bio-Techne’s exposure to secular growth drivers, such as cell and gene therapy and liquid biopsy development, makes it a compelling addition to the Portfolio.”
Likoper/Shutterstock.com
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $316.2 million in revenues, up 6% year-over-year on an organic basis and 4% on reported basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared Mairs & Power Balanced Fund’s views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
